poziotinib Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Poziotinib is a drug in development by Hanmi Pharmaceutical, Luye Pharma (China), and Spectrum Pharmaceuticals for various cancers.   Wikipedia

Chemistry

  • SMILES: C=CC(=O)N1CCC(Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2OC)CC1
  • InChIKey: LPFWVDIFUFFKJU-UHFFFAOYSA-N
  • Mol. Mass: 491.35
  • ALogP: 5.38
  • ChEMBL Molecules:
    poziotinib  
    poziotinib hydrochloride  
More Chemistry

Pharmacology

Alternative names

hm781-36 | hm-781-36b | hm781-36b | nov-120101 | poziotinib

Organizations (17)

Research & Development (17)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (14)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (14)


 

Breast Neoplasms (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Colorectal Neoplasms (Phase 2)

Esophageal Neoplasms (Phase 2)

Glioblastoma (Phase 2)

Glioma (Phase 2)

Head and Neck Neoplasms (Phase 2)

Healthy Volunteers (Phase 1)

Lung Neoplasms (Phase 2)

Mutation (Phase 2)

Neoplasms (Phase 2)

Pharmacology (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Stomach Neoplasms (Phase 1/Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 24
  • # of Trial Organizations: 17

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue